Legal Representation
Attorney
Matthew A. Newboles
USPTO Deadlines
Application History
9 events| Date | Code | Type | Description |
|---|---|---|---|
| Feb 18, 2025 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Feb 18, 2025 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Sep 28, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Sep 28, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sep 28, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Sep 26, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Aug 20, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Aug 20, 2024 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Mar 18, 2024 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
medicines, drugs and active synthetic peptides used for the prevention and treatment of inflammatory diseases, autoimmune diseases, immune-mediated diseases, infectious diseases, diseases of the central nervous system ("CNS") and abatement of acute and chronic rejection of tissue and organ in transplant recipients
Additional Information
Design Mark
The mark consists of an abstract phoenix with its wings raised high, where the mark "PHOENIX PEPTIDES" is underlined and is located between the raised wings.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
USPTO Documents
Loading USPTO documents...